October 23, 2017 9:18 PM ET

Biotechnology

Company Overview of DNA2.0, Inc.

Company Overview

DNA2.0, Inc., a synthetic biology company, provides gene synthesis and bioengineering solutions worldwide. It offers synthetic genes for academia, government and the pharmaceutical, chemical, agricultural, and biotechnology industries. Its solutions include Gene Designer Software that captures the entire gene design process in an application; gene optimization; gene synthesis; expression vectors genes for protein expression; and protein engineering. The company was founded in 2003 and is based in Menlo Park, California.

1140 O'Brien Drive

Suite A

Menlo Park, CA 94025

United States

Founded in 2003

Phone:

650-853-8347

Fax:

650-618-2697

Key Executives for DNA2.0, Inc.

Co-Founder, Chief Executive Officer and President
Co-Founder and Chief Commercial Officer
Co-Founder and Chief Scientific Officer
Co-Founder and Chief Information Officer
Chief Operating Officer and General Counsel
Age: 58
Compensation as of Fiscal Year 2017.

DNA2.0, Inc. Key Developments

ATUM Presents at 2017 World Congress on Industrial Biotechnology, Jul-23-2017

ATUM Presents at 2017 World Congress on Industrial Biotechnology, Jul-23-2017 . Venue: Palais des congrès de Montréal, Montréal, Quebec, Canada. Speakers: Claes Gustafsson, Chief Commercial Officer.

ATUM and Horizon Discovery Announces Collaboration and Technology Cross-License to Simplify and Speed Bioproduction Cell Line Development

ATUM and Horizon Discovery announced they have signed a cross-license agreement for Horizon’s CHO SOURCE platform and ATUM’s vector technology to speed development of highly productive stable cell lines for drug development. ATUM has licensed Horizon’s CHO SOURCE platform, including the Glutamine Synthetase (GS) Knock-Out CHO K1 (Chinese hamster ovary) line, and will use its proprietary Leap-In Transposase Technology to offer cell line development services. Horizon has exclusively licensed a vector suite developed by ATUM for the CHO SOURCE platform, to provide a complete cell line solution to its customers. Together, these technologies enable expression of complex biologics for customers of both ATUM and Horizon. ATUM is also offering Horizon customers a no-fee evaluation license for the transposase system. The CHO SOURCE platform increases stringency of selection as compared with historical platforms based around chemical inhibition such as Methionine Sulphoximine (MSX) and Methotrexate (MTX). The result is more rapid identification of clones expressing a biotherapeutic product at industry-relevant levels. CHO SOURCE is a commercially disruptive platform based on a one-time fee for access for full commercial use. The Horizon GS knockout cell line has been developed specifically to address the growing needs of biotech companies and CMOs in biological manufacturing. As part of the CHO SOURCE Platform, this fully traceable and GMP banked line is specifically designed for customers who want to rapidly implement an improved solution but without sacrificing time or putting quality at risk.

ATUM Licenses Gene Design Software to Thermo Fisher Scientific

ATUM announced that the company has signed a patent licensing agreement that gives Thermo Fisher Scientific access to the company’s novel gene design platform. Gene Designer 2.0 software, introduced by ATUM in 2005, captures the entire gene design process in one efficient application, using a range of design tools purposely built for the task: Intelligent algorithms for in silico cloning, codon optimization, back translation and primer design.; Graphically rich molecular view to display, annotate and edit constructs.; Customizable database to store, manage, and track genetic element, genes and constructs.; Drag-and-drop interface for moving sequence elements within or between constructs.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
\
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
NYC2012, Inc. United States
Tax Management Inc United States
Bertelsmann AG Europe

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact DNA2.0, Inc., please visit www.atum.bio. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.